期刊文献+

替吉奥联合奥沙利铂与改良FOLFOX6方案一线治疗进展期胃癌的随机对照研究 被引量:6

Randomized controlled trial on S-1 combined with oxaliplatin and modified FOLFOX6 in the first-line therapy of advanced gastric cancer
下载PDF
导出
摘要 目的比较国产替吉奥联合奥沙利铂方案(SOX)与改良FOLFOX6方案(mFOLFOX6)一线治疗局部晚期或转移性胃癌的近期疗效、远期生存及安全性。方法 40例进展期胃癌患者随机分为A、B组,A组采用SOX联合化疗方案,B组采用mFOLFOX6方案。2组患者均接受至少2周期化疗,每2周期评判1次近期疗效。结果 A组客观有效率、疾病控制率、中位疾病进展时间、中位生存期、1年生存率分别为45.0%、80.0%、6.0个月、15.0个月和45.0%;B组分别为40.0%、90.0%、5.5个月、11.0个月和35.0%。2组客观有效率及生存期无显著差异。2组不良反应均为血液系统毒性、恶心/呕吐和外周神经毒性,A组不良反应整体略轻微,但无显著性差异。结论氟尿嘧啶类药物联合奥沙利铂一线治疗进展期胃癌有较好的近期和远期疗效;替吉奥口服与氟尿嘧啶静脉化疗在疗效上无显著差异,不良反应均可耐受,可根据患者个体状况选择应用。 Objective To compare the nearterm therapeutic effect, long - term survival and safety of homemade S- 1 combined with oxaliplatin (SOX) and modified FOLFOX6 (mFOLFOX6) in the first - line therapy of local advanced or metastatic gastric cancer. Methods Forty patients with advanced gastric cancer were randomly divided into group A and group B. Group A adopted SOX combined with chemotherapy, while group B was applied with mFOLFOX6. Patients in both groups received at least two cycles of chemotherapy, and the nearterm therapeutic effects were evaluated once every two weeks. Results The objective response rate (ORR), disease control rate (DCR), median time to progression (mTTP), median overall survival (mOS) and one - year survival rate of group A were 45.0 %, 80.0 %, 6.0 months, 15.0 months and 45.0 %, respectively, whereas those of group B were 40.0 %, 90.0 %, 5.5 months, 11.0 months and 35.0 %. There were no significant differences between ORR and OS of the two groups. The adverse reactions of both groups included hematologic toxicity, nausea/vomiting and peripheral nerve toxicity, and those of group A were milder on the whole, but there were no marked differences. Conclusion Fluorouracil - like drugs combined with oxaliplatin have better short - term and long - term therapeutic effects in the firstline treatment of advanced gastric cancer. The therapeutic effects of orallytaken S- 1 and fluomuracil intravenous chemotherapy have no conspicuous difference, and both adverse reactions can be tolerated, so they can be selected for application according to individual condition.
出处 《实用临床医药杂志》 CAS 2013年第3期63-65,共3页 Journal of Clinical Medicine in Practice
基金 中国高校医学期刊临床专项资金(11220276)
关键词 进展期胃癌 替吉奥 奥沙利铂 化学治疗 advanced gastric carcinoma S- 1 oxa|iplatin chemotherapy
  • 相关文献

参考文献12

  • 1秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 2Van Cutsem E,Moiseyenko V M,Tjulandin S,et al.PhaseⅢstudy of docetaxel and cisplatin plus fluorouracil comparedwith cisplatin and fluorouracil as first-line therapy for ad-vanced gastric cancer:a report of the V325 Study Group[J].J Clin Oncol,2006,24(31):4991.
  • 3Cunningham D,Starling N,Rao S,et al.Capecitabine andoxaliplatin for advanced esophagogastric cance[J].N Engl JMed,2008,358(1):36.
  • 4Kang Y K,Kang W K,Shin D B,et al.Capecitabine/cis-platin versus 5-fluorouracil/cisplatin as first-line therapy inpatients with advanced gastric cancer:a randomized phaseⅢnon-inferiority trial[J].Ann Oncol,2009,20(4):666.
  • 5严冬,戴红.FOLFOX方案治疗局部进展期或转移性胃癌[J].中华肿瘤杂志,2009,31(3):217-219. 被引量:22
  • 6袁梅琴,钟海钧,杨云山.S-1治疗进展期胃癌的研究进展[J].国际肿瘤学杂志,2011,38(4):289-291. 被引量:4
  • 7Koizumi W,Narahara H,Hara T,et al.S-1 plus cisplatinversus S-1 alone for first-line treatment of advanced gastriccancer(SPIRITS trial):a phaseⅢtrial[J].Lancet Oncol,2008,9(3):215.
  • 8Ajani J A,Rodriguez W,Bodoky G,et al.Multicenter phaseⅢcomparison of cisplatin/S-1 with cisplatin/infusional fluo-rouracil in advanced gastric or gastroesophageal adenocarcino-ma study:the FLAGS trial[J].J Clin Oncol,2010,28(9):1547.
  • 9邱国钦,许丽贞,林智才,陈玉强.替吉奥联合顺铂治疗进展期胃癌的近期疗效观察[J].临床肿瘤学杂志,2011,16(8):728-731. 被引量:7
  • 10李小平,郑磊贞,章莉,陈思宇,顾建春.替吉奥联合顺铂与FOLFOX4方案治疗晚期胃癌的疗效比较[J].肿瘤学杂志,2012,18(3):230-231. 被引量:6

二级参考文献79

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2Cunningham D,Allum WH,Stenning SP,菅鑫妍.手术期间化学疗法与单独手术治疗可切除的胃食管癌疗效比较[J].中国处方药,2006,5(8):59-60. 被引量:434
  • 3秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 4De Vita F, Orditura M, Matano E, et al. A phase Ⅱ study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J cancer, 2005, 92:1644-1649.
  • 5Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer, 1999, 35:1059-1064.
  • 6Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori, 2002, 88 : 21- 27.
  • 7Kim NK, Park YS, Heo DS, et al. A phase Ⅲ randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer, 1993, 71:3813-3818.
  • 8Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase Ⅲ trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomyein in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol, 2003, 21:54-59.
  • 9Raymond E, Lawrence R, Izbicka E, et al. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res, 1998, 4 : 1021-1029.
  • 10Bleiberg H. Oxaliplatin (L-OHP) : a new reality in colorectal cancer. Br J Cancer, 1998, 77 Suppl 4:1-3.

共引文献396

同被引文献54

  • 1郭颖英,方伟虹,谢淑萍.替吉奥联合奥沙利铂治疗进展期胃癌疗效观察[J].浙江中医药大学学报,2010,34(5):783-783. 被引量:22
  • 2樊卫飞,王峻,孟丽娟,刘福银,蒲骁麟,杨民.替吉奥联合奥沙利铂一线治疗老年晚期胃癌的疗效分析[J].实用老年医学,2013,27(3):240-243. 被引量:12
  • 3季加孚.我国胃癌防治研究三十年回顾[J].中国肿瘤临床,2013,40(22):1345-1351.
  • 4Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of ox-alipl- atin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study) [J]. Ann Oneol, 2010, 21(5): 1001-1005.
  • 5白璐.替吉奥联合奥沙利铂治疗晚期胃癌的临床研究[J].承德医学院,2012.
  • 6Huang D, Ba Y, Xiong J,et al. A multicentre randomised trial comparing weekly paclitaxel q- S-1 with weekly paclitaxel q- 5-fluorouracil for patients with advanced gastric cancer[J].Eur J Cancer, 2013, 49(14): 2995-3002.
  • 7Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase Ill comparison of :cisplatin/S-1 with cisplatin/iMusional fluorouracil in advanced gastric or gastroesophageal adenocareinoma study: the FLAGS trial [J]. J Clin Oncol,2010, 28(9): 1547-1553.
  • 8Yoshida M, Ishiguro M, Ikejiri K, et al. S-1 as adjuvant chemotherapy for stage III colon eancer: a randomized phase Ill study (ACTS-CC trial)[J]. Ann Oneol, 2014, 25 (9): 1743-1749.
  • 9Ajani JA, Buyse M, Liehinitser M, et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocareinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study [J]. Eur J Cancer, 2013, 49(17): 3616-3624.
  • 10何忠杰,江荣科,朱丹丹,刘磊.奥沙利铂联合替吉奥胶囊治疗晚期胃癌的临床观察[J].实用癌症杂志,2010,25(3):286-288. 被引量:74

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部